Mercian Corporation

Chugai Seiyaku Kabushiki Kaisha

Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Mercian Corporation and Eisai Co., Ltd.

Kazuyuki Dobashi

Takeo Yoshioka

Takashi Nakashima

Motoko Matsufuji

Kunio Isshiki

Tomohiro Sameshima

Masanori Fujita

Koji Takeda

Takurou Tsuruta

Tadashi Terasawa

Kiyoshi Okamoto

Mitsuo Nagai

Yoshihiko Kotake

Jun Niijima

Satoshi Yamamoto

Toshio Tsuchida

Masashi Yoshida

Yoshiharu Mizui

Toshimitsu Uenaka

Naoto Kawamura

Takao Yamori

Susumu Takeda

Naoki Asai

Akira Arisawa

Takashi Sakai

Akifumi Okuda

Tomonari Yamada

Masao Iwata

Keisuke Komeda

Koji Norihisa

Kumiko Kishi

Yoshio Watanabe

Yasuhiro Funahashi

Taro Semba

Toshiaki Wakabayashi

Naoki Matsumoto

Rena Kawase

Nobuaki Naruse

The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution ofsp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it. 

Bioactive substance

The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution ofsp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it

Physiologically active substances

A method for preparing at least one hydroxycholesterol chosen from the group consisting of 25-hydroxycholesterol, 17,25-dihydroxycholesterol and 25,26-dihydroxycholesterol by biological hydroxylation of cholesterol, and the aforementioned dihydroxycholesterols. In the above biological hydroxylation, a microorganism is used which has the abovementioned hydroxylation capacity and which belongs to the genus Amycolata and the genus Sphingomonas.

Dihydroxycholesterol hydroxylated at 17- and 25-positions

This invention provides DNA fragments for efficiently preparing a protein having asymmetric hydrolase activity for 4-substituted 1,4-dihydropyridine derivatives, transformants obtained by using such a DNA fragment, and a process for preparing the aforesaid enzyme. Specifically, an isolated gene derived from the chromosome of and encoding a protein having asymmetric hydrolase activity for 4-substituted 1,4-dihydropyridine derivatives, plasmids having the aforesaid gene integrated thereinto, transformants obtained by using such a plasmid, and a process for preparing the aforesaid enzyme by using such a transformant are disclosed. A process for the enzymatic conversion of 4-substituted 1,4-dihydropyridine derivatives by using the aforesaid enzyme is also disclosed.

Gene encoding a protein having asymmetric hydrolase activity for 4-substituted 1,4-dihydropyridine derivatives and its expression product

Process for producing hydroxylated cholesterols and

Gene encoding a protein having symmetric hydrolase activity for

A biological process for producing steroids hydroxylated at the 25-position thereof comprises adding steroids (excluding cholesterol) to the cells or culture liquid of a microorganism of the genus Amycolata or Sphingomonas capable of hydroxylating the steroids at the 25-position thereof to convert a hydrogen atom bonded to a carbon atom at the 25-position of each steroid into hydroxyl group. By this process, steroids(other than cholesterol) can be biologically hydroxylated at the 25-position by using microorganisms other than those of the genus Streptomyces.

Biological process for producing steroids hydroxylated at the 25-position

1,4-dihydropyridine derivatives

Growing community of inventors

Kanagawa, Japan

Kazuyuki Dobashi